期刊
NEUROREPORT
卷 31, 期 9, 页码 663-671出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/WNR.0000000000001466
关键词
Alzheimer's disease; amyloid beta peptide; apoptosis; cognitive deficits; icariin
资金
- National Natural Science Foundation of China [81860710, 81650030]
- Guizhou Science Cooperation Foundation Project [20161165]
- Joint project of Zunyi Science and Technology Bureau [2016-08, 2017-29, 2017-53, 2018-160, 2018167, 2018-171]
- Open Funds of Laboratory of Basic Pharmacology of Ministry of Education [JCYL-K-012]
- Guizhou Provincial Administration of Traditional Chinese Medicine Project [QZYY-2016-018, QZYY-2018-098]
- Joint International Research Laboratory of Ethnomedicine of Ministry of Education [JCYL-K-012]
Effective therapeutic drugs for prevent or reverse the pathobiology of Alzheimer's disease (AD) have not been developed. Icariin (ICA), a prenylated flavonol glycoside derived from the traditional Chinese herb Epimedium sagittatum, exerts a variety of pharmacological activities and shows promise in the treatment and prevention of AD. This study investigated the neuroprotective effects of ICA in SAMP8 mice model of aspects of early AD and explored potential underlying mechanisms. Our results showed that intragastric administration of ICA could reverse the learning and memory impairment of SAMP8 mice in the Morris water maze. Western blot of hippocampal specimens revealed that ICA down-regulated the expression of BACE1 to reduce the expression of cytotoxic A beta(1-42). Furthermore, ICA siginificantly increase the Bcl-2/Bax ratio by increasing the expression of anti-apoptotic protein Bcl-2, and decreasing the expression of pro-apoptotic protein Bax, and thus inhibit neurons apoptosis. These findings indicate that ICA could improve cognitive deficits by reducing the deposition of beta(1-42) and inhibition of neurons apoptosis and provide further evidence for the clinical efficacy of ICA in the treatment of AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据